My SciELO
Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Anales de Medicina Interna
Print version ISSN 0212-7199
Abstract
BONILLA HERNAN, Mª G.; COBO IBANEZ, T.; MIGUEL MENDIETA, E. de and MARTIN-MOLA, E.. Infliximab (anti-TNF alfa) in the treatment of adult Still’s disease: Two cases. An. Med. Interna (Madrid) [online]. 2004, vol.21, n.1, pp.23-26. ISSN 0212-7199.
Adult Still´s disease is a systemic inflammatory disorder of unknown etiolgy. First-line treatment for Still´s disease includes nonsteroidal anti-inflammatory drugs and corticosteroids. In refractory cases o when the dose of corticosteroid is unacceptbly high, other disease modifiying antirheumatic drugs have been used. But recent study showed the efficacy anti-TNF therapy in adult Sill´s disease refractory to conventional therapy We report a favourable response to infliximab in two patients who has proved resistant to conventional therapy.
Keywords : Adult Still´s disease; Infliximab; Anti-TNF-a treatment.